Viropro, a public company incorporated in Nevada, focuses on developing cell lines and biopharmaceutical processes. The company's core mission is to advance the field of biopharmaceutical manufacturing by creating efficient and reliable processes that can be out-licensed to international partners. Viropro's primary offerings include biosimilar cell lines and manufacturing processes, aimed at enhancing the production and distribution of biopharmaceutical products globally.
Notable affiliated individuals and investors remain unspecified, but Viropro's key achievements include establishing partnerships with international entities to out-license their developed manufacturing processes. This strategic approach has enabled the company to make a significant impact on the global biopharmaceutical market, particularly in the area of biosimilars. Viropro's contributions help streamline the production of essential biopharmaceuticals, thereby supporting broader access to these critical medicines.
